A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

NCT ID: NCT01455857

Last Updated: 2015-08-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

460 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase 3 study to examine whether treatment with ITCA-650 60 mcg/day or 40 mcg/day is superior to placebo when added to current therapy in reducing HbA1c in patients with type 2 diabetes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ITCA 650 40 mcg/day

Group Type EXPERIMENTAL

ITCA 650

Intervention Type DRUG

ITCA 650 is exenatide in DUROS

ITCA 650 60 mcg/day

Group Type EXPERIMENTAL

ITCA 650

Intervention Type DRUG

ITCA 650 is exenatide in DUROS

ITCA placebo

Group Type PLACEBO_COMPARATOR

ITCA placebo

Intervention Type OTHER

Formulation in DUROS (no exenatide)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ITCA 650

ITCA 650 is exenatide in DUROS

Intervention Type DRUG

ITCA placebo

Formulation in DUROS (no exenatide)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HbA1c between 7.5% - 10%
* On diet \& exercise, metformin (MET), sulfonylurea (SU) or thiazolidinedione (TZD) alone or in combination or combined (SU + TZD) or in combination with Met + SU, Met + TZD, Met + TZD + SU
* BMI between 25 \& 45 kg/m2

Exclusion Criteria

* taking DPP-4 inhibitors, exenatide, liraglutide, alpha glucosidase inhibitors, meglitinides or insulin within last 3 months
* history of pancreatitis
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Intarcia Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Study Site

Birmingham, Alabama, United States

Site Status

Study Site

Gulf Shores, Alabama, United States

Site Status

Study Site

Huntsville, Alabama, United States

Site Status

Study Site

Chandler, Arizona, United States

Site Status

Study Site

Goodyear, Arizona, United States

Site Status

Study Site

Phoenix, Arizona, United States

Site Status

Study Site

Little Rock, Arkansas, United States

Site Status

Study Site

Chula Vista, California, United States

Site Status

Study Site

Fresno, California, United States

Site Status

Intarcia

Hayward, California, United States

Site Status

Study Site

Long Beach, California, United States

Site Status

Study Site

Los Angeles, California, United States

Site Status

Study Site

National City, California, United States

Site Status

Study Site

Port Hueneme, California, United States

Site Status

Study Site

San Jose, California, United States

Site Status

Study Site

San Mateo, California, United States

Site Status

Study Site

Tustin, California, United States

Site Status

Study Site

Valley Village, California, United States

Site Status

Study Site

Walnut Creek, California, United States

Site Status

Study Site

Watsonville, California, United States

Site Status

Study Site

Colorado Springs, Colorado, United States

Site Status

Study Site

Colorado Springs, Colorado, United States

Site Status

Study Site

Boca Raton, Florida, United States

Site Status

Study Site

Bradenton, Florida, United States

Site Status

Study Site

Celebration, Florida, United States

Site Status

Study Site

Clearwater, Florida, United States

Site Status

Study Site

Coral Gables, Florida, United States

Site Status

Study Site

Daytona Beach, Florida, United States

Site Status

Study Site

Hollywood, Florida, United States

Site Status

Study Site

Jacksonville, Florida, United States

Site Status

Study Site

Jacksonville, Florida, United States

Site Status

Study Site

Jacksonville, Florida, United States

Site Status

Study Site

Miami, Florida, United States

Site Status

Study Site

Miami, Florida, United States

Site Status

Study Site

Miami, Florida, United States

Site Status

Study Site

Miami, Florida, United States

Site Status

Study Site

Miami, Florida, United States

Site Status

Study Site

New Port Richey, Florida, United States

Site Status

Study Site

North Miami Beach, Florida, United States

Site Status

Study Site

Orlando, Florida, United States

Site Status

Study Site

Palm Harbor, Florida, United States

Site Status

Study Site

Pembroke Pines, Florida, United States

Site Status

Study Site

Ponte Vedra, Florida, United States

Site Status

Study Site

Tampa, Florida, United States

Site Status

Study Site

Atlanta, Georgia, United States

Site Status

Study Site

Canton, Georgia, United States

Site Status

Study Site

Idaho Falls, Idaho, United States

Site Status

Study Site

Meridian, Idaho, United States

Site Status

Study Site

Chicago, Illinois, United States

Site Status

Study Site

Chicago, Illinois, United States

Site Status

Study Site

Chicago, Illinois, United States

Site Status

Study Site

Evansville, Illinois, United States

Site Status

Study Site

Avon, Indiana, United States

Site Status

Study Site

Evansville, Indiana, United States

Site Status

Study Site

Franklin, Indiana, United States

Site Status

Study Site

Greenfield, Indiana, United States

Site Status

Study Site

Muncie, Indiana, United States

Site Status

Study Site

Valparaiso, Indiana, United States

Site Status

Study Site

Des Moines, Iowa, United States

Site Status

Study Site

Newton, Kansas, United States

Site Status

Study Site

Metaire, Louisiana, United States

Site Status

Study Site

Metairie, Louisiana, United States

Site Status

Study Site

Metarie, Louisiana, United States

Site Status

Study Site

New Orleans, Louisiana, United States

Site Status

Study Site

Baltimore, Maryland, United States

Site Status

Study Site

Brockton, Massachusetts, United States

Site Status

Study Site

Rochester, Michigan, United States

Site Status

Study Site

Ypsilanti, Michigan, United States

Site Status

Study Site

Kansas City, Missouri, United States

Site Status

Study Site

Billings, Montana, United States

Site Status

Study Site

Lincoln, Nebraska, United States

Site Status

Study Site

Las Vegas, Nevada, United States

Site Status

Study Site

Toms River, New Jersey, United States

Site Status

Study Site

Brooklyn, New York, United States

Site Status

Study Site

Endwell, New York, United States

Site Status

Study Site

Staten Island, New York, United States

Site Status

Study Site

Charlotte, North Carolina, United States

Site Status

Study Site

Charlotte, North Carolina, United States

Site Status

Study Site

Durham, North Carolina, United States

Site Status

Study Site

Greensboro, North Carolina, United States

Site Status

Study Site

Hickory, North Carolina, United States

Site Status

Study Site

Moorehead City, North Carolina, United States

Site Status

Study Site

Mooresville, North Carolina, United States

Site Status

Study Site

Salisbury, North Carolina, United States

Site Status

Study Site

Wilmington, North Carolina, United States

Site Status

Study Site

Winston-Salem, North Carolina, United States

Site Status

Study Site

Cincinnati, Ohio, United States

Site Status

Study Site

Cincinnati, Ohio, United States

Site Status

Study Site

Columbus, Ohio, United States

Site Status

Study Site

Franklin, Ohio, United States

Site Status

Study Site

Toledo, Ohio, United States

Site Status

Study Site

Norman, Oklahoma, United States

Site Status

Study Site

Oklahoma City, Oklahoma, United States

Site Status

Study Site

Bend, Oregon, United States

Site Status

Study Site

Uniontown, Pennsylvania, United States

Site Status

Study Site

Greer, South Carolina, United States

Site Status

Study Site

North Myrtle Beach, South Carolina, United States

Site Status

Study Site

Dakota Dunes, South Dakota, United States

Site Status

Study Site

Knoxville, Tennessee, United States

Site Status

Study Site

Memphis, Tennessee, United States

Site Status

Study Site

Austin, Texas, United States

Site Status

Study Site

Austin, Texas, United States

Site Status

Study Site

Carrolton, Texas, United States

Site Status

Study Site

Corpus Cristi, Texas, United States

Site Status

Study Site

Dallas, Texas, United States

Site Status

Study Site

Dallas, Texas, United States

Site Status

Study Site

Fort Worth, Texas, United States

Site Status

Study Site

Houston, Texas, United States

Site Status

Study Site

Houston, Texas, United States

Site Status

Study Site

Houston, Texas, United States

Site Status

Study Site

San Angelo, Texas, United States

Site Status

Study Site

San Antonio, Texas, United States

Site Status

Study Site

San Antonio, Texas, United States

Site Status

Study Site

Sugar Land, Texas, United States

Site Status

Study Site

Tomball, Texas, United States

Site Status

Study Site

Danville, Virginia, United States

Site Status

Study Site

Norfolk, Virginia, United States

Site Status

Study Site

Richmond, Virginia, United States

Site Status

Study Site

Port Orchard, Washington, United States

Site Status

Study Site

Renton, Washington, United States

Site Status

Study Site

Spokane, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Rosenstock J, Buse JB, Azeem R, Prabhakar P, Kjems L, Huang H, Baron MA. Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial. Diabetes Care. 2018 Feb;41(2):333-340. doi: 10.2337/dc17-1306. Epub 2017 Dec 14.

Reference Type DERIVED
PMID: 29242349 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ITCA 650-CLP-103

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dose Response Study in Japanese Patients
NCT00261417 TERMINATED PHASE2